Livarol in the treatment of chronic vulvovaginal candidiasis
DOI:
https://doi.org/10.18370/2309-4117.2017.35.81-83Keywords:
chronic vulvovaginal candidiasis, vaginal suppositories, effectiveness of treatment, ketoconazole, LivarolAbstract
The article presents the results of the study of treatment of women with chronic vulvovaginal candidiasis by vaginal suppositories Livarol, which contain 400 mg of ketoconazole.
Treatment was carried out according to two schemes. The main group (I) consisted of 22 women with chronic vulvovaginal candidiasis, who were prescribed treatment during the clinical manifestations of the disease in the form of Livarol in vaginal suppositories overnight during 10 days, then for three menstrual cycles in the same dosage during 5 days behind 7–10 days before the onset of menstruation. The comparison group (II) included 10 women with the same pathology, who were prescribed treatment only during the clinical manifestations of the disease in the form of Livarol in vaginal suppositories overnight during 10 days in one course. All patients were comparable in age and reproductive function and were treated on an outpatient basis.
The efficacy of treatment was assessed based on the disappearance of clinical symptoms and complaints (itching, burning, pain, caseous vaginal discharge), the lack of positive laboratory tests for the presence of fungal and pathogenic flora after 3, 6, 12 days and 1–10 months from the start of treatment. Therapy in the first group, which in the first stage provided for the elimination of exacerbation of chronic candidiasis by 10-day appointment of vaginal suppositories with ketoconazole, and at the second stage – 3-fold antiretroviral treatment for 5 days through 1 month, was more effective (90.9%). A single course of local treatment of chronic vulvovaginal candidiasis by Livarol within 10 days is less effective (60.0%).
The advantages of local use of ketoconazole are the rapid arresting of vulvovaginal candidiasis, a high concentration of antimycotic on the mucosa, the minimum frequency of side effects, the rapid normalization of the vaginal biocenosis, and the elimination of the effects of exo- and endocervicitis due to not only antimycotic but also antimicrobial action.
References
- Dolgo-Saburova, Y.V. Clinical and laboratory features of chronic recurrent candidiasis of genitalia in women. Thesis abstract for PhD degree. St. Petersburg (2006): 22 p.
- Mirzabalayeva, A.K. Candidiasis of the genitals in women in the practice of obstetrician-gynecologist. Tutorial. St. Petersburg (2009): 52 p.
- Prilepskaya, V.N., Bayramova, G.R. “Vulvovaginal candidiasis – modern ways of solving the problem.” The difficult patient 4.9 (2006): 1–4.
- Bingham, J.S. “What to do with the patient with recurrent vulvovaginal candidiasis.” Sex Transm Inf 75 (1999): 7.
- Jilek, P., et al. Factors associated with recurrent vulvovaginal candidiasis dietary intake, cloting, sexual activities, personal hygiene, antibiotic use and allergies. 3 Trends in Medical Mycology. Turin (2007): 99.
- Stamm, W.E. “Evaluating Guidelines.” Clinical Infectious Diseases 44 (2007): 775–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Т. С. Дивакова, Л. Д. Ржеусская
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.